Australian-based bio-separations company Memphasys Limited (ASX: MEM) has been granted two additional U.S. patents by the U.S. Patent and Trademark Office (USPTO), bringing the total number of patents granted to four.
The additional U.S. patents granted are:
1. Sperm separation by electrophoresis (U.S. Patent No. 10,946,346, issued on 16 March 2021)
A method of using at least one physically cross-linked biocompatible polymeric membrane in the separation of sperm by electrophoresis
2. Biocompatible polymeric membranes (U.S. Patent No. 10,962,537 issued on 30 March 2021)
A method of using at least one physically cross-linked biocompatible polymeric membrane in the separation of one or more macromolecules and/or cells by electrophoresis.
Executive Chairman, Alison Coutts, said Memphasys also owns several pending patent applications in Australia, Europe, the USA and various Asian countries and has sole licensing rights from the University of Newcastle on three further patents granted in Australia, the UK and the USA pertaining to sperm cell separation by electrophoresis.
In addition, Memphasys has registered FELIX as a trade mark for its ‘Felix’ sperm separation devices in Australia, the US, the EU and India. Trade mark applications for FELIX have also been filed in Canada, China and Japan.
We are delighted that the USPTO has granted these two U.S. patents which further strengthens Memphasys’ comprehensive patent portfolio and supports our unique bioseparations technology,” Ms Coutts said.
“The Felix device uses a suite of novel technologies to enable the quick and gentle separation of high quality sperm from a semen sample for use in human IVF procedures. With the granting of these patents the company can progress its activities with greater certainty in its intellectual property rights.”
